Pulmicort 1 MG/2 ML respule UD 2ML
Ended Awarded
- Contract number
- SPE2DB25FD7K4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,357
Award facts
- Contract value 100% obligated
- $15,356.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $15,356.55 delivery order to AmerisourceBergen Drug Corp for Pulmicort 1 mg/2 mL Respule UD 2 mL, a corticosteroid inhalation suspension commonly used for asthma and chronic obstructive pulmonary disease management. Issued on July 30, 2025, with completion scheduled for July 31, 2025, this firm fixed-price delivery order carries no set-aside designation and represents a competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive global range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling medical supply needs across multiple therapeutic domains through competitively awarded, non-set-aside delivery orders with firm fixed pricing. The DLA's Pharmaceutical Prime Vendor Global Program is planning to establish Generation V contracts with multiple regional awards, positioning AmerisourceBergen alongside other contractors to continue supporting military and federal healthcare requirements.
Quick answers
Who was awarded contract SPE2DB25FD7K4?
SPE2DB25FD7K4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 30, 2025.
How much is contract SPE2DB25FD7K4 worth?
The government has obligated $15,357 on SPE2DB25FD7K4.
Is contract SPE2DB25FD7K4 an order under another contract?
Yes. SPE2DB25FD7K4 is a delivery order under SPE2DB20D1100, an indefinite delivery contract.
Was contract SPE2DB25FD7K4 competed?
The extent of competition for SPE2DB25FD7K4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award